Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taysha Gene TherapiesTSHA -2.71%33 PB Ratio is 4.22 as of Sep. 12, 2026, which is 21% below its 10-year median of 5.32. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,214 Biotechnology companies, Taysha Gene Therapies ranks worse than 65.16% on this metric.
The historical rank and industry rank for Taysha Gene Therapies's PB Ratio or its related term are showing as below:
TSHA'
s PB Ratio Range Over the Past 10 Years
Min: 2.69 Med: 5.32 Max: 153.33
Current: 4.22
During the past 7 years, Taysha Gene Therapies's highest PB Ratio was 153.33. The lowest was 2.69. And the median was 5.32.
TSHA's PB Ratio is ranked worse than 65.16% of 1214
companies
in the Biotechnology industry
Industry Median: 2.865
vs TSHA: 4.22
During the past 12 months, Taysha Gene Therapies's average Book Value Per Share Growth Rate was 30.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 286.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -30.60% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Taysha Gene Therapies was 286.50% per year. The lowest was -60.80% per year. And the median was -48.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Taysha Gene Therapies (TSHA) has a PB Ratio of 4.22 as of Sep. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Taysha Gene Therapies and its competitors. This is 21% below median its historical median of 5.32. Over the past decade, Taysha Gene Therapies' PB Ratio has ranged from 2.69 to 153.33. According to the industry distribution chart, Taysha Gene Therapies ranks #791 out of 1214 companies in the Biotechnology industry, placing it in the top 65.2%.
Is Taysha Gene Therapies' PB Ratio too high?
Taysha Gene Therapies' current PB Ratio of 4.22 is 21% below median its 10-year median of 5.32. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 153.33. The Biotechnology industry median PB Ratio is 2.87. Taysha Gene Therapies' value of 4.22 is 47.3% above this industry median. Based on the distribution chart, Taysha Gene Therapies ranks #791 out of 1214 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' PB Ratio compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #791 out of 1214 companies for PB Ratio. This places Taysha Gene Therapies in the lower half of its industry. The industry median PB Ratio is 2.87. Taysha Gene Therapies' value of 4.22 is 47.3% above this benchmark. Historically, Taysha Gene Therapies' own PB Ratio has ranged from 2.69 to 153.33 over the past decade. While the company's 10-year median is 5.32 vs. the industry median of 2.87, Taysha Gene Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,214 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taysha Gene Therapies's current PB Ratio of 4.22 is 47.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Taysha Gene Therapies and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current PB Ratio is 4.22, which is 21% below median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current PB Ratio is 4.22, which is 21% below median its 10-year median of 5.32 and 47.3% above the Biotechnology industry median of 2.87. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current PB Ratio is 4.22 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
PB Ratio: 4.22 (21% below median its 10-year median of 5.32)
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
Industry Position: 47.3% above the Biotechnology median (#791 of 1214)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
